Sign Out
Avaxim 80: Posology: Primary vaccination (first dose): The primary vaccination is provided by a 0.5 ml vaccine dose.
Booster: After the primary vaccination, a booster dose of 0.5 ml is recommended to achieve long-term protection. This booster dose should be administered 6 months to 10 years after this first dose.
Method of administration: AVAXIM 80 U Pediatric should be administered into a muscle (to minimise local reactions), in the child's upper outer arm.
If the child suffers from haemophilia or if he/she is easily prone to bruising or bleeding, the vaccine can exceptionally be administered under the skin.
This vaccine must never be administered into a blood vessel.
The doctor or nurse should not inject the vaccine into the skin.
The vaccine must not be administered into the buttock.
The doctor or nurse will shake the syringe immediately before the injection and make sure that the liquid is cloudy and whitish and that no foreign particles are in it.
If the child forgets to use AVAXIM 80 U Pediatric suspension for injection in pre-filled syringe: The doctor will decide when to administer this missing dose.
If the child stops using AVAXIM 80 U PEDIATRIC suspension for injection in pre-filled syringe: Not applicable.
If there are any further questions on the use of this medicine, advise the patient to ask the doctor or pharmacist.
Avaxim 160: The vaccine will be administered by a health professional trained to the use of vaccines and equipped to respond to any severe allergic reaction following the injection.
Dosage: One 0.5 ml dose of AVAXIM 160 U is administered to subjects from the age of 16 years.
The patient will be protected against hepatitis A about 14 days after the first dose.
In order to obtain long-term protection against hepatitis A, the patient will need a second injection (booster) of hepatitis A vaccine. It is generally administered between 6 and 12 months after the first dose, and can be administered up to 36 months after the first dose. This booster will protect the patient against hepatitis A beyond 10 years.
AVAXIM 160 U can also be administered as a booster dose of the hepatitis A vaccination if the patient has received the first injection with the combined typhoid fever (Vi purified polysaccharide) and hepatitis A (inactivated) vaccine 6 to 36 months earlier.
Method of administration: AVAXIM 160 U must be administered into a muscle in the outer upper part of the patient's arm.
If the patient has bleeding problems or bruises easily, the vaccine can be administered under the skin.
Avoid injecting the vaccine into the skin or into a blood vessel.
This vaccine must not be administered into the buttock.
If the patient forgets to use Avaxim 160 U: Not applicable.
If the patient stops using Avaxim 160 U: Not applicable.
If there are any further questions on the use of this medicine, advise the patient to ask the doctor or pharmacist.
